Biotechnology company RXi Pharmaceuticals has reported positive data from a second Phase I multi-dose study of an sd-rxRNA compound, RXI 109, which targets connective tissue growth factor (CTGF).

RXI 109 is being developed to treat abnormal dermal scars such as hypertrophic scars and keloids in combination with scar revision surgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In the study, subjects were treated with three intradermal doses of RXI 109 over a period of two weeks after receiving small skin incisions in the abdomen.

Comprising three cohorts of three healthy volunteers each, the subjects received RXI 109 on one side of the abdomen, and placebo on the other side in the dose escalating study.

After monitoring the subjects for safety and local and systemic side effects over an 84 day-period, the study noted that multiple intradermal injections of RXI 109 was well tolerated.

See Also:

"The work done in the last year has confirmed that our proprietary self-delivering RNAi technology reduces CTGF mRNA in humans in line with its mechanism of action."

The study also concluded that the treatment with RXI 109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RXi Pharmaceuticals president and CEO Dr Geert Cauwenbergh said the results indicate that multiple intradermal injections of RXI 109 are well tolerated with minimal and mild side-effects.

"The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action," Cauwenbergh said.

"Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI 109 as compared to placebo."

First Phase I study demonstrated the efficacy of a single dose of the drug in lowering the actual protein content for CTGF also in a dose-dependent manner.

The company now plans to begin Phase II development in patients with hypertrophic scars and keloids.